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The Genetic Landscape of Programmed Death Ligand-1 (PD-L1)
Alterations in Head and Neck Cancer
Thomas E. Heineman, MD ; Adam Widman, MD; Edward C. Kuan, MD; Maie St John, MD, PhD
Objectives: Nivolumab has recently been shown in the phase III clinical trial CheckMate-141 to have superior survival
rates compared to the current standard of care chemotherapy for recurrent or metastatic platinum-resistant head and neck
squamous cell carcinoma (HNSCC). Nivolumab targets the immune inhibitory receptor programmed cell death 1 (PD-1). Pro-
grammed cell death ligand 1 (PD-L1) genomics have been poorly characterized in the context of HNSCC, including expression
levels of PD-L1 in individual tumors as well as related up or down-regulated genes that might function as co-targets.
Study Design: Data mining of The Cancer Genome Atlas (TCGA)
Methods: 530 patients with HNSCC were pulled from the TCGA using cBioPortal. Primary tumor site data was available
in 279 of the samples (52.6%), of which oral cavity was the most common site (61.6%) followed by larynx (25.8%). Other
PD-1-sensitive tumors were analyzed to compare PD-L1 expression in HNSCC relative to other tumors including bladder, renal
cell carcinoma, melanoma, and lung carcinomas.
Results: A significant fraction of HNSCC tumors have genetic alterations in PD-L1 (6.2%). HNSCC has the highest PD-L1
expression of all of the tumor types examined, with a median 60-fold increase. Several important genes were identified in
this study including Caspase 7, ZFYVE9, and Plg-R(KT) that have a strong relationship with alterations in PD-L1.
Conclusion: In light of the role of PD-1 and PD-L1 as key immunotherapy targets in HNSCC, several potential co-targets
identified in this study warrant further investigation. Further, while the number of genetic alterations were small in head and
neck carcinomas, alterations in PD-L1 expression were highly significant.
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INTRODUCTION
The Programmed Death 1 (PD-1) immune check-
point comprises the PD-1 T-cell co-inhibitory receptor
and the Programmed death ligand 1 and 2 and PD-L2
ligands.1 The pathway mediates immune resistance in
the local environment. Monoclonal antibodies blocking
PD-1 activate the immune system against several
tumors, including kidney, lung, melanoma, and colon.2
PD-L1 expression in tumor specimens can identify
patients that are likely to have a response to PD-1 blockade
with monoclonal antibodies, and PD-L1 expression tests
are approved by the Food and Drug Administration to
guide clinical decision making in advanced non–small-cell
lung cancer and melanoma.3 Tumor mutational burden,
which creates new neoantigens for immune recognition,
also influences tumor responsiveness to anti–PD-1 therapy,
as has the presence of DNA mismatch repair defects.4,5
Despite the development of novel therapies, many
patients with squamous cell carcinoma of the head and
neck (HNSCC) have a poor prognosis. In addition to the
traditional teaching of a strong association with tobacco
and alcohol, human papilloma virus (HPV) infection has
also recently been identified as an important oncogenic
risk factor.6,7 Cancer genomics of HNSCC has shown a
high tumor mutational burden.4 Patients with meta-
static, platinum refractory disease have poor outcomes
when chemotherapy is used in the relapsed setting.8 PD-
1 inhibition with nivolumab can improve survival in
these patients, and tumors with high PD-1 expression
respond better to PD-1 inhibition than those with no
PD-1 expression.9 In non–small-cell lung cancer and
melanoma, patients are much more likely to benefit
from PD-1 inhibition when PD-L1 is expressed.3
Herein we sought to determine gene expression pat-
terns, co-occurring mutations, and copy number varia-
tions in HNSCC tumors known to have alterations in
PD-L1, and to compare HNSCC PD-L1 expression with
expression in other cancers that are known to respond
favorably to anti-PD-1/PD-L1 therapy.
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MATERIALS AND METHODS
Patient Population and Tumor Genetics
The results included in our study are based upon data
generated by the head and neck cancer (HNSCC) data found
within the Cancer Genome Atlas (TCGA) Research Network
(http://cancergenome.nih.gov/). The data set included 530
patients with HNSCC, of which 279 patients had full tumor
sequencing and protein expression analysis data available and
530 patients had somatic copy number alteration (SCNA) data
available.10 The patient population was 72.8 percent male with
the tumor stage breakdown as follows: 5.1% Stage I, 14.5%
Stage II, 15.5% Stage III, 48.9% Stage IVA, 2.3% Stage IVB,
0.2% Stage IVC. Tumor Subsite data was available for 279
patients including 61.6% oral cavity, 25.8% larynx, 11.8% oro-
pharynx, and 0.7% hypopharynx. PD-L1 expression data in the
head and neck cancer data set was compared to other cancers
that have shown sensitivity to PD-1 inhibition including blad-
der, papillary, clear cell and chromophobe renal cell carinomas,
melanoma as well as squamous and adenocarcinoma of the lung
with data available in the TCGA. The TCGA data was analyzed
using the open-source web program cBioPortal.11,12 Figures
were generated using Plotly (Montreal, Canada), as functional-
ity built into cBioPortal.
Somatic Copy Number Alteration (SCNA)
Analysis
Copy number alterations were calculated using Genomic
Identification of Significant Target in Cancer 2.0 (GISTIC).13 This
validated method identifies alterations that drive cancer growth by
utilizing a probabilistic method for defining background rates of
copy-number alterations from focal cancer-associated changes. The
SCNA results were made available through the cBioPortal.
Protein Expression Analysis
Protein expression analysis was performed using a reverse
phase protein array (RPPA) analysis. This is a high throughput
platform that can analyze protein expression levels of a large
number of biological samples using a dot-blot platform and
high-quality antibodies. The RPPA results were made available
through the cBioPortal.
Statistics
Statistical significance was calculated using imbedded
algorithms within cBioPortal. A p-value<0.05 was used as a
cutoff of significance level.
RESULTS
The genetic fingerprint of HNSCC within the TCGA
dataset showed preservation of PD-1 in the large major-
ity of cases (93.8%). There were no PD-L1 somatic muta-
tions seen in 279 samples with whole genome
sequencing. When assessing somatic copy number alter-
ations, 25 of 530 samples amplified (4.7%) and 8 of 530
samples deleted (1.5%) PD-L1.
We performed a comprehensive somatic copy num-
ber analysis of the alteration of 19,238 possible genes
and found 112 co-occurred or were mutually excluded
with statistical significance when PD-L1 was altered.
Figure 1 is a volcano plot of these results. Supplemental
Table 1 details all 112 genes and displays the percen-
tages and p-values for each.
A similar analysis of deep deletions instead of
amplification of 11,843 genes found 31 genes that co-
occurred or were mutually excluded with statistical sig-
nificance. Figure 2 is a volcano plot of these results.
Supplemental Table 2 details all 31 genes and displays
the percentages and p-values for each.
Further, we performed a protein expression analysis
using RPPA and found 5 proteins (IGFBP2, CASP7,
CDKN2A, NF2, ITGA2) to have statistically significant
changes when PD-L1 was altered. Figure 3 is a volcano
plot of these results. Supplemental Table 3 details all 5
genes and displays the percentages and p-values for each.
Of note, the signal to noise ratio was very high for insulin-
like growth factor binding protein 2 (over-expressed,
p-value50.00069). In contradistinction caspase 7 was
significantly under-expressed (p-value50.0127).
While there were not any individual point muta-
tions found within PD-L1 in the dataset, we analyzed
any associated mutations found in other genes when
Fig. 2. A volcano plot of an enrichment analysis of putative copy-
number alterations (Deep deletions) from GISTIC with altered copy
numbers of PD-L1.
Fig. 1. A volcano plot of an enrichment analysis of putative copy-
number alterations (Amplifications) from GISTIC with altered copy
numbers of PD-L1.
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PD-L1 was either amplified or deleted. There were 83
genes out of 12,682 analyzed that had a statistically sig-
nificant relationship with PD-L1. Figure 4 is a volcano
plot of these results. Supplemental Table 4 details all 83
genes and displays the percentages and p-values for
each.
Survival was not significantly affected in patients
with or without genetic alterations in PD-L1 (p-value5
0.647). The median survival of the PD-L1 altered group
was 47.9 months, and was 56.9 months for the PL-1
unaltered group. A survival curve is given in Figure 5.
Of note, there were 33 patients included in the PL-1
altered group, of which 16 were deceased and 17 were
censored.
Expression of PD-L1 may be independent of copy
number variations or somatic mutations. Figure 6 illus-
trates several different tumor types and expression
levels of PD-L1. Interestingly, HNSCC has the highest
PD-L1 expression of all of the examined tumor types.
The median expression of PD-L1 is a 60-fold increase
from baseline.
DISCUSSION
The PD-1–blocking antibodies pembrolizumab and
nivolumab are promising therapies for patients with
advanced metastatic melanoma and non–small-cell lung
cancer.14,15 Nivolumab was recently approved for the
treatment of a renal cell carcinoma, and has now shown
antitumor efficacy in HNSCC.8,16 Despite promising
results, some cancers appear to be refractory to
anti-PD-1 therapy. Factors known to be associated with
anti-PD-1 response include tumor PD-L1 expression,
high tumor mutational burden, and the presence of CD8
T cells at the invasive tumor margin.17 Determining
further mechanisms of PD-1 resistance and new thera-
peutic targets remains critical.
The incidence of PD-L1 expression in HNSCC
appears most similar to non-small cell lung cancer.
Median PD-L1 expression in HNSCC exceeds that of
other anti-PD-1 sensitive cancers.
Plg-R(KT) was found to be have the strongest asso-
ciation to PD-L1 in both deletion and amplification copy
number variations. Plg-R(KT) is a plasminogen receptor
found to be a control point regulating cell surface prote-
olysis. Plg-R(KT) is broadly expressed in migratory cells
(e.g. leukocytes) and in breast cancer, leukemic and neu-
ronal cells.18 The gene plays an important role in macro-
phage recruitment in the inflammatory process, and its
absence significantly impairs macrophage recruitment in
mice.19 Plg-R(KT) activates plasminogen, which acts to
inhibit cellular apoptosis.20 Therapeutic knockdown of
Plg-R(KT) could promote cancer cell apoptosis.
The most significant gene associated with muta-
tions in PD-L1 altered cancers was zinc finger FYVE
domain containing 9 (ZFYVE9). ZFYVE9 recruits
unphosphorylated SMAD2/SMAD3 to the TGF-beta
Fig. 5. Survival curves of patients without alterations in PD-L1 (black)
compared to patients with genetic alterations in PD-L1 (gray).
Fig. 3. A volcano plot of an enrichment analysis of under-
expressed and over-expressed proteins when PD-L1 expression is
altered.
Fig. 4. A volcano plot of an enrichment analysis of co-occurring
mutations when PD-L1 expression is altered.
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receptor. Once phosphorylated, SMAD2/SMAD3 dissoci-
ates from ZFYVE9 and translocates into the nucleus.
TGF-beta signaling has several known functions in both
tumor growth and suppression, but may help tumor cells
proliferate and escape immune response.21 This path-
way’s relationship to PD-L1 merits further investigation.
It may be a candidate target for multimodality therapy
to prevent PD-1 resistance or to provide synergistic effi-
cacy with PD-1 inhibition.
Caspase 7 was found to have the strongest negative
association with PD-L1 expression. The caspase family
of proteins play an intricate role in cell apoptosis and
are frequently down-regulated in cancer.22
The TCGA dataset gives an accurate portrayal of
tumor cell expression of PD-L1 in HNSCC. Notably
absent are PD-L1 expression data from tumor immune
infiltrates. In colorectal cancer, high tumor neoantigen
load correlated positively with lymphocytic infiltration
and disease-specific survival.23 Given the known somatic
mutational burden in HNSCC,24 and the significant
improvement in survival seen in HNSCC tumors in
which PD-L1 expression was greater than 1% (Check-
mate 141), it is likely that looking purely at tumor gene
expression within the TCGA can characterize the unique
measures HNSCC tumors use to evade the host immune
system and inform on genetic targets that may be useful
in the treatment of HNSCC. An evaluation and further
characterization of the tumor microenvironment within
HNSCC and several other cancers could similarly pro-
duce new targets designed to activate the immune sys-
tem against cancer.
Taken together, genes most associated with PD-L1
expression in HNSCC are intricately involved in
immune pathways, and the complex dysregulation of the
immune response may make HNSCC vulnerable to other
immunotherapy targets. Perhaps associated genetic
abnormalities in PD-L1 positive tumors can contribute
to a “gene-expression signature” that can identify
HNSCC tumors most likely to respond to anti-PD1
therapy similar to risk signatures that help guide clini-
cal therapy in breast cancer.25
CONCLUSION
The PD-L1 ligand is a powerful mechanism for can-
cer cell evasion of immune detection. Our algorithm,
which analyzes PD-LI expression in the context of asso-
ciated genetic mutations, can predict actionable gene
targets and may be informative for tumor prognosis. PD-
L1 expression in tumor specimens may identify patients
that are likely to have a response to PD-1 blockade with
monoclonal antibodies, with a 60-fold increase in PD-L1
expression in our studied tumor samples. PD-L1 expres-
sion tests are already approved by the Food and Drug
Administration to guide clinical decision-making in
advanced non–small-cell lung cancer and melanoma. We
introduce this study as further evidence for a prospec-
tive study in HNSCC using a PD-L1 expression-based
protocol to select patients that would be favorable candi-
dates to receive PD-L1 therapy.
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